Lake Street analyst Brooks O’Neil notes that Stryker (SYK) announced a definitive agreement for the sale of its U.S. spinal implants business and plans to sell its related international business. Alphatec (ATEC) is likely to benefit from ongoing spine industry disruption, contends the analyst, who believes an inflection to profitability will “make a big difference for many investors” and affirms a Buy rating and our $18 price target on Alphatec shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- Alphatec price target raised to $21 from $20 at Barclays
- Alphatec price target raised to $19 from $16 at Jefferies
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Alphatec sees Q4 revenue $175.5M-$177.0M , consensus $170.35M
- Alphatec sees FY25 revenue $732M, consensus $729.77M
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue